Drug-tolerant "persister" tumor cells underlie emergence of drug-resistant clones and contribute to relapse and disease progression. Here we report that resistance to the BCL-2 targeting drug ABT-199 in models of mantle cell lymphoma and double-hit lymphoma evolves from outgrowth of persister clones displaying loss of 18q21 amplicons that harbor BCL2. Further, persister status is generated via adaptive super-enhancer remodeling that reprograms transcription and offers opportunities for overcoming ABT-199 resistance. Notably, pharmacoproteomic and pharmacogenomic screens revealed that persisters are vulnerable to inhibition of the transcriptional machinery and especially to inhibition of cyclin-dependent kinase 7 (CDK7), which is essential for the transcriptional reprogramming that drives and sustains ABT-199 resistance. Thus, transcription-targeting agents offer new approaches to disable drug resistance in B-cell lymphomas.
Pubmed ID: 31085176 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Software package for interpreting gene expression data. Used for interpretation of a large-scale experiment by identifying pathways and processes.
View all literature mentionsSystem that classifies genes by their functions, using published scientific experimental evidence and evolutionary relationships to predict function even in absence of direct experimental evidence. Orthologs view is curated orthology relationships between genes for human, mouse, rat, fish, worm, and fly.
View all literature mentionsA quantitative proteomics software package for analyzing large-scale mass-spectrometric data sets. It is a set of algorithms that include peak detection and scoring of peptides, mass calibration, database searches for protein identification, protein quantification, and provides summary statistics.
View all literature mentionsThis monoclonal targets Ikaros
View all literature mentionsThis monoclonal targets c-Myc antibody [Y69]
View all literature mentionsThis monoclonal targets IRF5
View all literature mentionsThis monoclonal targets β-Actin
View all literature mentionsThis polyclonal targets Human Bcl2A1
View all literature mentionsThis monoclonal targets RNAPII
View all literature mentionsThis polyclonal targets TCF-4
View all literature mentionsThis polyclonal targets H3K27ac
View all literature mentionsThis monoclonal targets RNA Polymerase II subunit B1 phosphorylated at Ser5 of the C-terminal domain
View all literature mentionsThis monoclonal targets RNA polymerase II subunit B1 phosphorylated at Ser7 of the C-terminal domain
View all literature mentionsThis monoclonal targets RNA polymerase II subunit B1 (phospho CTD Ser-2) clone 3E10
View all literature mentionsThis monoclonal targets CDK7 (MO1) Mouse mAb
View all literature mentionsThis monoclonal targets Bcl-11A
View all literature mentionsThis unknown targets Bcl-xL
View all literature mentionsThis monoclonal targets Cleaved PARP (Asp214)
View all literature mentionsThis monoclonal targets NOXA
View all literature mentionsThis monoclonal targets FOXC1
View all literature mentionsThis polyclonal targets Bcl-2 (Human Specific)
View all literature mentionsThis monoclonal targets Bak
View all literature mentionsThis monoclonal targets Bim (C34C5) Rabbit mAb
View all literature mentionsCell line HBL-2 [Human mantle cell lymphoma] is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsThis monoclonal targets c-Myc antibody [Y69]
View all literature mentions